IMpassion131

NCT03125902 📎

Regimen

Experimental
Atezolizumab 840 mg Q2W + paclitaxel 90 mg/m2 weekly (D1,8,15 Q4W) until progression.
Control
Placebo + paclitaxel weekly.

Population

Previously untreated locally advanced or metastatic triple-negative breast cancer.

Key finding

IMpassion131 failed to confirm IMpassion130: paclitaxel (instead of nab-paclitaxel) + atezolizumab showed no PFS or OS benefit in PD-L1+ metastatic TNBC. Led to FDA withdrawing atezolizumab TNBC indication in 2021.

Source: PMID 34219000

Timeline

  • Publication: 2021 Aug

Guideline citations

  • NCCN BREAST